Home
|
About us
|
Contact us
About AWMSG
All Wales Medicines Strategy Group (AWMSG)
New Medicines Group (NMG)
All Wales Prescribing Advisory Group (AWPAG)
Meetings
Appraisals
Appraisal information
Patients/carers/patient organisations
Healthcare professionals
Pharmaceutical industry
Search and reports
Search and browse
Reports
Medicines management
About
Forthcoming work programme
National prescribing indicators
Clinical effectiveness prescribing programme
Appraisal monitoring
In-patient medication administration record
Patient information leaflets
Library
insulin degludec/liraglutide (Xultophy®)
Reference No. 2544
Publication date:
18/11/2015
Appraisal information
insulin degludec/liraglutide (Xultophy®) 100 units/ml/3.6 mg/ml solution for injection
Company:
Novo Nordisk Ltd
BNF category:
Endocrine system
NMG meeting date:
09/09/2015
AWMSG meeting date:
21/10/2015
Submission Type:
Full Submission
Status:
Recommended with restrictions
Advice No:
2715
Ratification by Welsh Government:
17/11/2015
Current Progress
Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government
AWMSG advice
Insulin degludec/liraglutide (Xultophy®) is recommended as an option for restricted use within NHS Wales. Insulin degludec/liraglutide (Xultophy®) is licensed for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with a glucagon-like peptide protein-1 (GLP-1) receptor agonist or basal insulin do not provide adequate glycaemic control. Insulin degludec/liraglutide (Xultophy®) is restricted for use in combination with oral glucose-lowering medicinal products when these combined with basal insulin do not provide adequate glycaemic control. Insulin degludec/liraglutide (Xultophy®) is not recommended for use within NHS Wales outside of this subpopulation.
Final Appraisal Recommendation (FAR)
Download
insulin degludec_liraglutide (Xultophy) 2544 FAR
AWMSG Secretariat Appraisal Report (ASAR)
Download
insulin degludec_liraglutide (Xultophy) 2544 ASAR
Clinical Expert (CE) Summary
Download
insulin degludec_liraglutide (Xultophy) 2544 CE summary